This clinical trial is focused on studying the treatment of Non-Small Cell Lung Cancer (NSCLC), a common type of lung cancer. The study is comparing the effectiveness of a combination of two medications, savolitinib and osimertinib, against a standard treatment known as platinum-based doublet chemotherapy. Savolitinib, also known by its code name AZD6094, is a medication that targets specific proteins in cancer cells. Osimertinib, sometimes referred to as AZD9291, is a drug that targets mutations in the epidermal growth factor receptor (EGFR), which are often found in NSCLC. The purpose of the study is to determine how well the combination of savolitinib and osimertinib works compared to chemotherapy in patients with NSCLC who have specific genetic changes and have previously been treated with osimertinib.

Participants in the study will be randomly assigned to receive either the combination of savolitinib and osimertinib or the chemotherapy treatment. The study will monitor the participants over a period to see how the cancer responds to the treatments. The researchers will look at how long the participants live without the cancer getting worse, which is known as progression-free survival. They will also assess overall survival, which is the length of time participants live after starting the study. The study will also evaluate the safety and side effects of the treatments, as well as how the treatments affect symptoms like shortness of breath, cough, and chest pain.

This trial is open-label, meaning both the participants and the researchers know which treatment is being given. The study will continue until 2027, and it aims to provide valuable information on the best treatment options for patients with advanced or metastatic NSCLC who have specific genetic changes and have progressed after previous treatment with osimertinib.